The Biocodex Microbiota Foundation rewards international research proposals involving the microbiota and its implication in Women's Health and Disease.
The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Clinical Consortium Award (CCA) provides support to develop, maintain, and enhance the necessary collaborations and resources to rapidly execute phase 2 and/or phase 2-linked phase 1 (phase1/2) prostate cancer clinical trials. The primary intent of the PCRP Clinical Consortium Award is to combine the efforts of leading investigators across multiple institutions to expedite the clinical advancement of novel therapeutic interventions in prostate cancer to decrease the impact of the disease.
The fiscal year 2025 (FY25) Prostate Cancer Research Program (PCRP) Idea Development Award (IDA) supports new ideas that represent innovative approaches to prostate cancer research and have the potential to make an important contribution to the PCRP mission. All applications are required to address one or more of the FY25 PCRP Overarching Challenges.
Transformational Science Grants are intended for established, experienced, independent investigators affiliated with a research or academic institution whose proposed projects have substantial preliminary data, investigate hypotheses directly related to Dravet syndrome, and have potential to significantly impact the field of research.
Research Grant Awards are intended for established, experienced, independent investigators affiliated with a research or academic institution whose proposed projects investigate hypotheses directly related to Dravet syndrome. Proposals are scored according to NIH guidelines based on the quality of preliminary data, research design, feasibility, investigator’s qualifications, and overall impact. Grants are awarded for $250,000 over 2 years (beginning January 1 of each year), with indirect costs not to exceed 10% of the award.
The Childhood Eczema Challenge Grant is intended to stimulate early and mid-career scientists as they seek to build and sustain careers as research investigators and future thought leaders within this critical field of study
This award provides funding support for experienced researchers with recognized productivity — either within or outside the eczema field — to conduct highly innovative, cutting-edge investigations related to eczema. Data from this award can then be used to seek additional, larger-scale funding from the National Institutes of Health (NIH) or other funding entities to build on these discoveries.
This award is intended to promote research in topic areas of special interest that relate to NEA’s advancement of our overall research priorities for eczema. The availability of this grant category will be determined on an annual basis; topics of special interest may vary. For 2025, specific areas of research interest include: patient-centered outcomes research.
This award is intended to fuel early-stage ideas by supporting emerging investigators in testing new concepts, piloting experiments or exploring novel data analyses.
Vision Grants are intended to provide initial funding for novel, innovative research by promising young investigators that will advance progress towards detection, prevention, or treatment of preeclampsia, HELLP syndrome, and other hypertensive disorders of pregnancy. Post-doctoral, Clinical Fellows, or Early Stage Investigators only are eligible to apply.
The ultimate goal of this grant program is to drive research that will eliminate the delivery of pre-term babies as an intervention for severe preeclampsia, HELLP syndrome, and related hypertensive disorders of pregnancy.
Johnson & Johnson (J&J), US
